Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arenarine D
- Development stage
- Unknown
- Lead developer
- Xiamen University
01
Overview
Arenarine D: sourced facts only. name: "Mechanistic studies established DYRK1B and MYH9 as potential targets of Arenarine D." [PMID:42308607]; target: "Mechanistic studies established DYRK1B and MYH9 as potential targets of Arenarine D." [PMID:42308607]; target: "Mechanistic studies established DYRK1B and MYH9 as potential targets of Arenarine D." [PMID:42308607]; developer: "School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, Fujian, 361102, China." [PMID:42308607]
02
Targets
DYRK1B (Dual specificity tyrosine-phosphorylation-regulated kinase 1B)MYH9 (Non-muscle myosin IIA)
Beyond the preview
Go deeper on Arenarine D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arenarine D.